Geode Capital Management, LLC Compass Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

$1.21 Trillion
Q3 2024

A detailed history of Geode Capital Management, LLC transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 2,309,778 shares of CMPX stock, worth $3.67 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,309,778

Previous 2,290,683 0.83%

Holding current value

$3.67 Million

Previous $2.29 Million 85.55%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$0.8 - $1.88 $15,276 - $35,898	19,095 Added 0.83%	2,309,778 $4.25 Million
Q2 2024 Aug 09, 2024	BUY	$1.0 - $1.85 $215,348 - $398,393	215,348 Added 10.38%	2,290,683 $2.29 Million
Q1 2024 May 13, 2024	BUY	$1.2 - $2.29 $99,968 - $190,773	83,307 Added 4.18%	2,075,335 $4.11 Million
Q4 2023 Feb 13, 2024	BUY	$1.4 - $1.98 $139,589 - $197,419	99,707 Added 5.27%	1,992,028 $3.11 Million
Q3 2023 Nov 13, 2023	BUY	$1.87 - $3.25 $157,293 - $273,370	84,114 Added 4.65%	1,892,321 $3.73 Million
Q2 2023 Aug 11, 2023	BUY	$2.64 - $3.48 $2.44 Million - $3.22 Million	924,644 Added 104.65%	1,808,207 $5.75 Million
Q1 2023 May 15, 2023	BUY	$3.14 - $5.48 $293,009 - $511,366	93,315 Added 11.81%	883,563 $2.89 Million
Q4 2022 Feb 13, 2023	BUY	$2.55 - $5.41 $481,756 - $1.02 Million	188,924 Added 31.42%	790,248 $3.97 Million
Q3 2022 Nov 14, 2022	BUY	$1.9 - $3.37 $1.1 Million - $1.94 Million	576,467 Added 2319.13%	601,324 $1.37 Million
Q1 2022 May 13, 2022	BUY	$1.25 - $3.5 $31,071 - $86,999	24,857 New	24,857 $34,000

Others Institutions Holding CMPX

# of Institutions

Shares Held

92M

Call Options Held

Put Options Held

View Full List

About Compass Therapeutics, Inc.

Ticker CMPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 101,285,000
Market Cap $161M
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...

More about CMPX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Compass Therapeutics, Inc. Transaction History